POU class 3 homeobox 1Genealiases: OCT6 · OTF6 · SCIP
Q-omics provides the consensus-scored POU3F1 profile across patient tissues and cancer cell-line models. POU3F1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, POU3F1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, POU3F1 RNA expression shows 15,265 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight SCLC, KICH, and ESCA as cancer lineages where POU3F1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POU3F1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POU3F1 survival associations across molecular data types. POU3F1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POU3F1 RNA expression–survival associations across cancer types. High POU3F1 expression shows unfavorable associations in MESO, LGG, LAML and OV, but favorable associations in SCLC and ESCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify SCLC as the clearest survival context for POU3F1 RNA expression.
This table summarizes POU3F1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for POU3F1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POU3F1 shows lower tumor expression in KICH and KIRP and higher tumor expression in HNSC, KIRC, LUSC and LIHC. The KICH box plot shows higher POU3F1 RNA expression in normal versus tumor tissue (log2 FC = −0.249, t-test p < 0.001).
This table shows molecular features associated with POU3F1 in patient tissues and cancer cell lines. In patient samples, POU3F1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, POU3F1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
